Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Nimish Maheshwari, an independent analyst and co-founder of Beat The Street, is an investing platform garnering more than 1,00,000+ followers across social media. 
His deep insights and forensic analysis have been featured in some of India's most prominent publications, including the Economic Times, The Morning Context, The Ken,  Dalal Street Investment Journal, Moneylife by Sucheta Dalal, and TheCore.in.
He has a keen eye for identifying red flags in Indian listed companies and has identified exclusive red flags earlier in Adani, Vedanta, Nykaa, Gland Pharma, Brightcom Group etc.

Market & Forensics Analyst

Business Breakdown: Pokarna Limited, A Niche Quartz Player Facing Challenge Due to US Tariff

Zydus Lifesciences: The PBC Catalyst, From Generics Volume to Specialty Value

The Beat Ideas: NLC India-A 1.17 Lakh Crores Capex, Renewable Focus

Business Breakdown: HP Adhesives- Building a Brand or Battling Giants

The Beat Ideas: Astral ~ Leader in PVC Pipes, Riding the Restocking Cycle

Business Breakdown: Associated Alcohols- The Spirit of Bold Expansion

The Beat Ideas: Finolex Industries Ltd ~ Vertically Integrated PVC Manufacturer

The Beat Ideas: Bajaj Consumer ~ A Turnaround Play Through Non- ADHO Business

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

Zydus Lifesciences Ltd / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/zydus-lifesciences-ltd" target="_blank" data-smartkarma-citation="entities:12914:1" rel="noopener">Zydus Lifesciences Ltd (ZYDUSLIF IN)</a> is a leading global healthcare company specializing in generic drugs, biosimilars, and innovative therapies across multiple therapeutic areas.</li>
<li>While the Revlimid slowdown risk looms, Zydus aims to offset this with a strong pipeline of new product launches and R&amp;D innovations.</li>
<li>Its secondary sales have consistently outpaced market growth, driven by strong performances in chronic and specialty products.</li>
</ul>



Zydus Lifesciences Ltd (ZYDUSLIF IN) is a leading global healthcare company specializing in generic drugs, biosimilars, and innovative therapies across multiple therapeutic areas.
While the Revlimid slowdown risk looms, Zydus aims to offset this with a strong pipeline of new product launches and R&amp;D innovations.
Its secondary sales have consistently outpaced market growth, driven by strong performances in chronic and specialty products.


Business Breakdown: Zydus Lifesciences ~ Bet on R&D and New Launches to Fill the Revenue Gap